{
    "clinical_study": {
        "@rank": "149500", 
        "arm_group": {
            "arm_group_label": "[18F]NAV4694", 
            "arm_group_type": "Experimental", 
            "description": "Single intravenous injection of 8.1 millicuries of [18F]NAV4694"
        }, 
        "brief_summary": {
            "textblock": "This is a phase 2, open-label, multiple-center, non-randomized single dose study to assess\n      the safety and efficacy of [18F]NAV4694 PET imaging in detecting beta-amyloid plaque in the\n      brain in subjects with probable AD compared with healthy volunteers."
        }, 
        "brief_title": "Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All participants:\n\n          -  is able to provide informed consent or assent, and exhibits adequate visual,\n             auditory, and communication capabilities to enable compliance with study procedures\n\n          -  should be able to perform the psychometric testing\n\n          -  has a modified Hachinski score ((Hachinski, et al., 2012; Rosen, et al., 1980) \u2264 4 at\n             screening\n\n          -  possesses a general health that permits adequate compliance with all study procedures\n             as ascertained by a detailed review of the medical history, surgical history,\n             laboratory and physical examination findings, which must be performed within 56 days\n             prior to administration of [18F]NAV4694\n\n          -  informed consent has been signed and dated by the subject and/or the subject's\n             legally authorized representative (LAR; for probable AD subjects)\n\n        Healthy Volunteers Only\n\n          -  is male or female and is between the age of 18 and 40 years (for younger HVs) or 55\n             to 85 years of age (for older HVs)\n\n          -  if female does not have childbearing potential: must be confirmed by either:\n             post-menopausal status; or history of surgical sterilization or of hysterectomy\n\n          -  if female has childbearing potential: must demonstrate a negative serum beta-HCG\n             level at screening and a negative urine pregnancy test on the day of injection (prior\n             to injection) consistent with a non-gravid state and agree to use two acceptable\n             forms of birth control\n\n          -  has no evidence of cognitive impairment as indicated by a clinical dementia rating\n             (CDR) (Morris, 1993) score of 0 (zero) and a score of \u2265 28 in the Mini-Mental State\n             Examination (MMSE) (Folstein, et al., 1975)\n\n          -  has MRI brain scan that has been judged as \"normal (age-appropriate)\" supporting the\n             lack of cerebrovascular disease (e.g., a white matter lesion score of 0, 1, or 2 and\n             a basal ganglia score of 0 to 1 on the ARWMC scale)\n\n        Probable Alzheimer's Disease Subjects Only\n\n          -  is male or female and is \u2265 55 of age, whereby females must be without childbearing\n             potential (confirmed by either:post-menopausal status; or history of surgical\n             sterilization or of hysterectomy)\n\n          -  presents with positive assessment for dementia of Alzheimer's type in accordance with\n             the DSM-IV-TR and probable AD according to the NINCDS-ADRDA criteria and fulfills\n             none of the exclusion criteria of either\n\n          -  does not fulfill the International Consensus Criteria (ICC) for probable diffuse Lewy\n             body disease (DLBD), the NINDS-AIREN for probable vascular dementia, or the Neary\n             criteria for frontotemporal dementia (FTD)  [Neary et al. 1998]\n\n          -  has a MMSE score between 16 and 23\n\n          -  has a CDR (Morris, 1993) score of 1 to 2\n\n          -  has a Cornell Scale for Depression in Dementia (CSDD; (Alexopoulos, et al., 1988))\n             score less than or equal to 18 (definite major depression)\n\n          -  MRI brain scan findings that do not reveal changes indicative of stroke and/or\n             generalized cerebrovascular disease changes (limited to: a white matter lesion score\n             of 0, 1, or 2 and a basal ganglia score of 0 or 1 on the ARWMC scale)\n\n          -  has a caregiver who is willing and able to attend study visits and perform the\n             psychometric tests requiring the presence of a caregiver\n\n        Exclusion Criteria:\n\n          -  has any contraindication to MRI examination, e.g., metal implants or phobia\n\n          -  is not able to lie down flat in the MRI and PET scanners\n\n          -  is scheduled for surgery and/or another invasive procedure within the time period of\n             up to 10 days after [18F]NAV4694 application\n\n          -  is medically unstable and whose clinical course during the observation period is\n             unpredictable, e.g., subjects within 14 days of myocardial infarction or stroke,\n             unstable subjects with previous surgery (within 7 days), subjects with advanced heart\n             insufficiency (NYHA stage IV), or with acute renal failure\n\n          -  has a history of exposure to any radiation > 30 mSv in the last year (e.g.,\n             occupational, diagnostic imaging, or radiation therapy)\n\n          -  is receiving drug therapy or other treatment that is known to lead to greatly\n             fluctuating values of the hematological or chemical laboratory parameters or to\n             severe side effects (e.g., chemotherapy)\n\n          -  has received anti-amyloid immunotherapy\n\n          -  has been previously enrolled in this study and received [18F]NAV4694 or participated\n             in a clinical study involving an investigational pharmaceutical product within 30\n             days prior to screening, and/or any radiopharmaceutical within 10 radioactive\n             half-lives prior to [18F]NAV4694 administration\n\n          -  has a brain tumor or other intracranial lesion, a disturbance of cerebrospinal fluid\n             (CSF) circulation (e.g., normal pressure hydrocephalus) and/or a history of serious\n             head trauma or brain surgery\n\n          -  has a history, physical, laboratory, or imaging findings indicative of a significant\n             neurological or psychiatric illness (other than AD for the subjects with probable AD)\n\n          -  has another untreated disease that can cause disturbance of brain function (e.g.\n             vitamin B12 or folic acid deficiency, disturbed thyroid function, anemia)\n\n          -  has a history of alcohol abuse or drug dependency in the 3 years prior to study entry\n             or is an alcoholic or drug addict as determined by the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680588", 
            "org_study_id": "NAV4-01"
        }, 
        "intervention": {
            "arm_group_label": "[18F]NAV4694", 
            "intervention_name": "[18F]NAV4694", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Alzheimer", 
        "lastchanged_date": "November 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06510"
                    }, 
                    "name": "Molecular NeuroImaging, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elk Grove Village", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60007"
                    }, 
                    "name": "Alexian Brothers Neurosciences Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana Medical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham & Women's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quincy", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02169"
                    }, 
                    "name": "Alzheimer's Disease Center, Quincy Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12208"
                    }, 
                    "name": "Neurological Associates of Albany"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Navidea Biopharmaceuticals", 
            "last_name": "Cornelia Reininger, M.D., PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate [18F]NAV4694 PET visual assessment by centralized readers for detection of cerebral beta-amyloid plaque in subjects diagnosed with probable Alzheimer's disease compared with similarly aged and young healthy volunteers.", 
            "measure": "[18F]NAV4694 PET visual assessment by centralized readers", 
            "safety_issue": "No", 
            "time_frame": "25 minutes post injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680588"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the incidence of adverse events after a single dose of [18F]NAV4694 PET in individuals diagnosed with probable AD and similarly aged and young healthy volunteers.", 
                "measure": "Assess the incidence of adverse events after a single dose of [18F]NAV4694", 
                "safety_issue": "Yes", 
                "time_frame": "7 Days"
            }, 
            {
                "description": "To evaluate [18F]NAV4694 PET quantitative assessment, by assessing standard uptake value ratios (SUVR) for detection of cerebral beta-amyloid plaque in subjects diagnosed with probable Alzheimer's disease compared with similarly aged and young healthy volunteers.", 
                "measure": "Evaluate [18F]NAV4694 PET quantitative assessment", 
                "safety_issue": "No", 
                "time_frame": "25 minutes post injection"
            }, 
            {
                "description": "To determine the correlation of neuro-psychiatric tests with the beta-amyloid plaque burden determined by correlating various baseline neuro-psychiatric test scores with the [18F]NAV4694 PET imaging results in subjects diagnosed with probable AD", 
                "measure": "Determine correlation of neuro-psychiatric tests with [18F]NAV4694 imaging", 
                "safety_issue": "No", 
                "time_frame": "25 minutes post injection"
            }, 
            {
                "description": "To assess changes in laboratory values after a single dose of [18F]NAV4694 PET in individuals diagnosed with probable AD and similarly aged and young healthy volunteers.", 
                "measure": "Assess changes in laboratory values after a single dose of [18F]NAV4694", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }
        ], 
        "source": "Navidea Biopharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Navidea Biopharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}